Villani et al. indicated that SGLT2 inhibitor, namely canagliflozin inhibits mitochondrial complex-I resulting in reduced prostate cancer cell proliferation, which was presented in their in vivo and in vitro study (Villani et al., 2016). Here, SLC5A2 is linked to Familial prostate cancer.